Literature DB >> 3143885

Protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 in infant rat infection model: new prospects for vaccine development.

K Saukkonen1, H Abdillahi, J T Poolman, M Leinonen.   

Abstract

The protective efficacy of monoclonal antibodies to class 1 and class 3 outer membrane proteins of Neisseria meningitidis B:15:P1.16 was tested in an infant rat infection model. Four monoclonal antibodies to class 1 protein had bactericidal titres exceeding 20,000 and they protected infant rats completely against bacterial challenge with meningococci carrying the same class 1 protein, P1.16. One monoclonal antibody to class 3 protein was highly bactericidal (titer greater than 20,000), whereas two others had no bactericidal activity. All these antibodies gave some protection from infection, resulting in mortalities varying from 66 to 83% as compared to 100% in control rats who had received either unrelated monoclonal antibody or saline. These results strongly speak for class 1 outer membrane protein as a vaccine candidate for meningococcus group B.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3143885     DOI: 10.1016/0882-4010(87)90059-3

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  43 in total

1.  Multiple mechanisms of phase variation of PorA in Neisseria meningitidis.

Authors:  A van der Ende; C T Hopman; J Dankert
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

2.  Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.

Authors:  Maija Toropainen; Leena Saarinen; Gestur Vidarsson; Helena Käyhty
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

3.  Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.

Authors:  E R van der Voort; P van der Ley; J van der Biezen; S George; O Tunnela; H van Dijken; B Kuipers; J Poolman
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 4.  Animal models for pathogenic Neisseria species.

Authors:  R J Arko
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

5.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

6.  Topology of outer membrane porins in pathogenic Neisseria spp.

Authors:  P van der Ley; J E Heckels; M Virji; P Hoogerhout; J T Poolman
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

7.  Use of transformation to construct antigenic hybrids of the class 1 outer membrane protein in Neisseria meningitidis.

Authors:  P van der Ley; J van der Biezen; P Hohenstein; C Peeters; J T Poolman
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

8.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

9.  Molecular characterization and adhesive properties of CF29K, an adhesin of Klebsiella pneumoniae strains involved in nosocomial infections.

Authors:  P Di Martino; Y Bertin; J P Girardeau; V Livrelli; B Joly; A Darfeuille-Michaud
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

10.  Molecular cloning and sequence analysis of the gene encoding OmpL1, a transmembrane outer membrane protein of pathogenic Leptospira spp.

Authors:  D A Haake; C I Champion; C Martinich; E S Shang; D R Blanco; J N Miller; M A Lovett
Journal:  J Bacteriol       Date:  1993-07       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.